Hepatitis C virus (HCV) NS3-NS4A protease is an attractive target for anti-HCV agents because of its important role in replication. An optimized fluorescence resonance energy transfer (FRET) substrate for NS3-NS4A protease, based on the sequence of the NS5A-5B cleavage site, was designed and synthesized. High-throughput screening of in-house compound libraries was performed using a FRET substrate FS10 (MOCAc-DKIVPC-SMSYK-Dnp) and MBP-NS3-NS4A fusion protein. Several hit compounds were found, including YZ-9577 (2-oxido-1,2,5-oxadiazole-3,4-diyl) bis (phenylmethanone) with potent inhibitory activity (IC50=1.6 μM) and good selectivity against other human serine proteases.
BartenschlagerRAhlborn-LaakeLMousJ & JacobsenH (1994) Kinetic and structural analyses of hepatitis C virus polyprotein processing. Journal of Virology68: 5045–5055.
2.
ChooQLRichmanKHHanJHBergerKLeeCDongCGallegosCCoitDMedina-SelbyR & BarrPJ (1991) Genetic organization and diversity of the hepatitis C virus. Proceedings of the National Academy of Sciences USA88: 2451–2455.
3.
ChuMMierzwaRHeLKingAPatelMPichardoJHartAButkiewiczN & PuarMS (1999) Isolation and structure of SCH 351633: A novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum. Bioorganic & Medicinal Chemistry9: 1949–1952.
4.
ColarussoSKochUGerlachBSteinkuhlerCDe FrancescoRAltamuraSMatassaVG & NarjesF (2003) Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: Discovery, initial SAR, and molecular modeling. Journal of Medicinal Chemistry46: 345–348.
5.
De FrancescoRTomeiLAltamuraSSummaV & MigliaccioG (2003) Approaching a new era for hepatitis C virus therapy: Inhibitors of the NS3–4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Research58: 1–16.
6.
FaillaCTomeiL & De FrancescoR (1994) Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. Journal of Virology68: 3753–3760.
7.
FieldsGBTianZ & BaranyG (1992) Principles and practice of solid phase peptide synthesis. In Synthetic Peptides: A User's Guide; pp. 77–183. Edited by GrantGA. New York: WH Freeman and Co.
8.
GlunzPWDoutyBD & DeciccoCP (2003) Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors. Bioorganic & Medicinal Chemistry13: 785–788.
9.
GrakouiAMcCourtDWWychowskiCFeinstoneSM & RiceCM (1993) Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites. Journal of Virology67: 2832–2843.
10.
HandaBKKeechEConwayEABroadhurstA & RitchieA (1995) Design and synthesis of a quenched fluorogenic peptide substrate for human cytomegalovirus proteinase. Antiviral Chemistry & Chemotherapy6: 255–261.
11.
HijikataMMizushimaHAkagiTMoriSKakiuchiNKatoNTanakaTKimuraK & ShimotohnoK (1993) Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. Journal of Virology67: 4665–4675.
12.
HinrichsenHBenhamouYWedemeyerHReiserMSentjensRECallejaJLFornsXErhardtACronleinJChavesRLYongCLNehmizG & SteinmannGG (2004) Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology127: 1347–1355.
13.
HolskinBPBukhtiyarovaMDunnBDBaurPde ChastonaryJ & PenningtonMW (1995) A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. Analytical Biochemistry226: 148–155.
14.
HoughtonMWeinerAHanJKuoG & ChooQL (1991) Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. Hepatology14: 381–388.
15.
InoueHSakashitaHShimizuYYamajiKYokotaTSudoKShigetaS & ShimotohnoK (1998) Expression of a hepatitis C virus NS3 protease-NS4A fusion protein in Escherichia coli. Biochemical & Biophysical Research Communications245: 478–482.
16.
KakiuchiNHijikataMKomadaYTanjiYHirowatariY & ShimotohnoK (1995) Bacterial expression and analysis of cleavage activity of HCV serine proteinase using recombinant and synthetic substrate. Biochemical & Biophysical Research Communications210: 1059–1065.
KakiuchiNNishikawaSHattoriM & ShimotohnoK (1999) A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase. Journal of Virological Methods80: 77–84.
19.
KatoNHijikataMOotsuyamaYNakagawaMOhkoshiSSugimuraT & ShimotohnoK (1990) Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proceedings of the National Academy of Sciences USA87: 9524–9528.
20.
KnightCGWillenbrockF & MurphyG (1992) A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Letters296: 263–266.
21.
LamarreDAndersonPCBaileyMBeaulieuPBolgerGBonneauPBosMCameronDRCartierMCordingleyMGFaucherAMGoudreauNKawaiSHKukoljGLagaceLLaPlanteSRNarjesHPoupartMARancourtJSentjensRESt GeorgeRSimoneauBSteinmannGThibeaultDTsantrizosYSWeldonSMYongCL & Llinas-BrunetM (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature426: 186–189.
22.
LinC & RiceCM (1995) The hepatitis C virus NS3 serine protease and NS4A cofactor: Establishment of a cell-free trans-processing assay. Proceedings of the National Academy of Sciences USA92: 7622–7626.
23.
MatayoshiEDWangGTKrafftGA & EricksonJ (1990) Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science247: 954–958.
24.
NagaseHFieldsCG & FieldsGB (1994) Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). Journal of Biological Chemistry269: 20952–20957.
25.
PawlotskyJM (2003) The nature of interferon-alpha resistance in hepatitis C virus infection. Current Opinion in Infectious Diseases16: 587–592.
26.
RancourtJCameronDRGorysVLamarreDPoirierMThibeaultD & Llinas-BrunetM (2004) Peptide-based inhibitors of the hepatitis C virus NS3 protease: Structure-activity relationship at the C-terminal position. Journal of Medicinal Chemistry47: 2511–2522.
27.
ShimizuYYamajiKMasuhoYYokotaTInoueHSudoKSatohS & ShimotohnoK (1996) Identification of the sequence on NS4A required for enhanced cleavage of the NS5A/5B site by Hepatitis C virus NS3 protease. Journal of Virology70: 127–132.
28.
SperandioDGangloffARLitvakJGoldsmithRHatayeJMWangVRSheltonEJElrodKJancJWClarkJMRiceKWeinheimerSYeungKSMeanwellNAHernandezDStaabAJVenablesBL & SpencerJR (2002) Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease. Bioorganic & Medicinal Chemistry Letters12: 3129–3133.
29.
SteinkuhlerCUrbaniATomeiLBiasiolGSardanaMBianchiEPessiA & DeFrancescoR (1996) Activity of purified hepatitis C virus protease NS3 on peptide substrates. Journal of Virology70: 6694–6700.
30.
SudoKInoueHShimizuYYamajiKKonnoKShigetaSKanekoTYokotaT & ShimotohnoK (1996) Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. Antiviral Research32: 9–18.
31.
SudoKMatsumotoYMatsushimaMFujiwaraMKonnoKShigetaS & YokotaT (1997a) Novel hepatitis C virus protease inhibitors: Thiazolidine derivatives. Biochemical & Biophysical Research Communications238: 643–647.
TakamizawaAMoriCFukeIManabeSMurakamiSFujitaJOnishiEAndohTYoshidaI & OkayamaH (1991) Structure and organization of the hepatitis C virus genome isolated from human carriers. Journal of Virology65: 1105–1113.
34.
TalianiMBianchiENarjesFFossatelliMUrbaniASteinkuhlerCDe FrancescoR & PessiA (1996) A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Analytical Biochemistry240: 60–67.
35.
WalkerMPApplebyTCZhongWLauJY & HongZ (2003) Hepatitis C virus therapies: Current treatments, targets and future perspectives. Antiviral Chemistry & Chemotherapy14: 1–21.
36.
WangQMJohnsonRBCohenJDVoyGTRichardsonJM & JungheimLN (1997) Development of a continuous fluorescence assay for rhinovirus 14 3C protease using synthetic peptides. Antiviral Chemistry and Chemotherapy8: 303–310.
37.
YamajiKShimizuYMasuhoY & ShimotohnoK (1995) Novel fluorescent substrate for assaying activity of hepatitis C virus NS3 serine protease. Japanese patent application number 07–217950; International application number PCT/JP96/02343.
38.
ZhangXSchmittACJiangWWassermanZ & DeciccoCP (2003) Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease. Bioorganic & Medicinal Chemistry Letters13: 1157–1160.
